{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T04:40:59Z","timestamp":1690000859806},"reference-count":0,"publisher":"Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy","issue":"1","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mediterr J Hematol Infect Dis"],"abstract":"<jats:p>Background: The second decade of this millennium was characterized by a widespread availability of chimeric antigen receptor T-cell (CAR-T)therapies to treat relapsed and refractory lymphomas.&#x0D;\nAs expected, the role and indication of allogeneic haematopoietic stem cell transplant(allo-HSCT)in the management of lymphoma changed. Currently a not unneglectable proportion of patients will be considered candidate for an allo-HSCT and the debate of which transplant platform should be offered is still active.&#x0D;\nObjectives:to report the outcome of patients affected with relapsed\/refractory lymphoma and transplanted following reduced intensity conditioning at King\u2019s College Hospital, London, between January 2009 and April2021. Methods: Conditioning was with fludarabine 150mg\/m2 and melphalan 140mg\/m2. The graft was unmanipulated G-CSF mobilized peripheral blood haematopoietic stem cells(PBSC). Graft-versus-host disease (GVHD) prophylaxis consisted of pre-transplant Campath at the total dose of 60 mg in unrelated donors and 30 mg in fully matched sibling donors, and ciclosporin.&#x0D;\nResults: One year and five years OS were87% and79.9%, respectively and median OS was not reached. Cumulative incidence of relapse was 16%.Incidence of acute GVHD was 48%(only grade I\/II); no cases of grade III\/IV were diagnosed. Chronic GVHD occurred in 39% of patients. TRM was 12%, with no cases developed within day 100 and 18months after the procedure.&#x0D;\nConclusions:The outcomes of heavily pretreated lymphoma patients are favorable with median OS and survival not reached after a median of 49months. In conclusion, even if some lymphoma subgroups can\u2019t be treated (yet) with advanced cellular therapies, this study confirms the role of allo-HSCT as a safe and curative strategy.<\/jats:p>","DOI":"10.4084\/mjhid.2023.041","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T13:46:27Z","timestamp":1689947187000},"page":"e2023041","source":"Crossref","is-referenced-by-count":0,"title":["FLUDARABINE-MELPHALAN-CAMPATH FOLLOWED BY UNMANIPULATED PERIPHERAL-BLOOD HAEMATOPOIETIC STEM CELLS CAN STILL CURE LYMPHOMA."],"prefix":"10.4084","volume":"15","author":[{"given":"Daniele","family":"Avenoso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"Alabdulwahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Kenyon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramila","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Dazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye Ting","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Anteh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mili Naresh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Kuhnl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piers","family":"Patten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Yallop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2554","published-online":{"date-parts":[[2023,6,29]]},"container-title":["Mediterranean Journal of Hematology and Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/www.mjhid.org\/index.php\/mjhid\/article\/download\/5334\/4367","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mjhid.org\/index.php\/mjhid\/article\/download\/5334\/4368","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mjhid.org\/index.php\/mjhid\/article\/download\/5334\/4367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T13:46:27Z","timestamp":1689947187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mjhid.org\/index.php\/mjhid\/article\/view\/5334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.4084\/mjhid.2023.041","relation":{},"ISSN":["2035-3006"],"issn-type":[{"value":"2035-3006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}